Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Rises By 234.4%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 8,509,923 shares, a growth of 234.4% from the April 15th total of 2,544,706 shares. Based on an average daily volume of 79,730,843 shares, the short-interest ratio is currently 0.1 days. Approximately 25.4% of the shares of the company are sold short.

Theriva Biologics Trading Down 9.3%

TOVX traded down $0.03 on Friday, hitting $0.29. The company had a trading volume of 2,596,802 shares, compared to its average volume of 45,280,248. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11. The company has a market cap of $9.82 million, a PE ratio of -0.01 and a beta of 1.17. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $0.86. The business’s fifty day simple moving average is $0.26 and its 200 day simple moving average is $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group raised Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Theriva Biologics currently has an average rating of “Buy” and an average target price of $1.00.

Institutional Trading of Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP purchased a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.